- Telehealth Visits
- Insurance plan information
Harish N. Vasudevan, MD, PhD
He | Him | HisRadiation Oncology- Telehealth Visits
- Insurance plan information
Harish N. Vasudevan, MD, PhD
He | Him | HisRadiation Oncology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Harish N. Vasudevan is a radiation oncologist who cares for children and adults with nervous system tumors.
With the goal of improving diagnosis and treatment, Vasudevan's research focuses on how certain signals within cells – in particular, those involving a family of proteins called receptor tyrosine kinases and the Ras signaling pathway – lead to cancer. He has a special interest in neurofibromatosis, a genetic disorder with numerous effects, including an increased risk of brain and nerve tumors.
Vasudevan completed his undergraduate studies at the California Institute of Technology. He earned his medical degree from the Icahn School of Medicine at Mount Sinai, where he also earned a doctorate in neuroscience. He completed a residency in radiation oncology at UCSF and served as chief resident.
Education & training
Board certification
- Radiology, American Board of Internal Medicine
Residency
- Radiation Oncology, University of California Mount Zion Medical Center
Internship
- Internal Medicine, California Pacific Medical Center GME
Degree
- MD, ICAHN School of Medicine at Mount Sinai
My expertise
Specialties
Conditions
- Plantar-Fascial Fibromatosis
- Dupuytren Contracture
- Hyperthermia
- Eye Cancer
Treatments
- Radiation Treatment
- Total Body Irradiation
- 3D Conformal Radiation Therapy
- Volumetric Modulated Arc Therapy
- Stereotactic Cranial Radiation
- Stereotactic Spine Radiosurgery
- Gamma Knife Radiosurgery
- Three-Dimensional Conformal Radiation Therapy
- Stereotactic Radiosurgery
My research
Publications
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.